

# Achim Rittmeyer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4923903/publications.pdf>

Version: 2024-02-01

36  
papers

9,866  
citations

361413

20  
h-index

377865

34  
g-index

42  
all docs

42  
docs citations

42  
times ranked

10163  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 21-33.	2.6	12
2	Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	2.0	1
3	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). <i>Lung Cancer</i> , 2021, 152, 174-184.	2.0	53
4	Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2021, 16, 140-150.	1.1	95
5	Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. , 2021, 9, e001882.		12
6	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. <i>Translational Lung Cancer Research</i> , 2021, 10, 3093-3105.	2.8	23
7	Update on recent key publications in lung oncology: picking up speed. <i>European Respiratory Review</i> , 2021, 30, 200300.	7.1	1
8	Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). <i>Lung Cancer</i> , 2021, 160, 17-27.	2.0	10
9	Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. <i>Translational Lung Cancer Research</i> , 2020, 9, 603-616.	2.8	21
10	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492095135.	1.3	24
11	Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 769-782.	2.0	9
12	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 924-937.	10.7	1,133
13	Abscopal effect in lung cancer: three case reports and a concise review. <i>Immunotherapy</i> , 2019, 11, 1445-1461.	2.0	37
14	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 64-72.	7.0	159
15	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. <i>Lung Cancer</i> , 2019, 128, 105-112.	2.0	126
16	Multidisciplinary treatment of lung cancer in older patients: A review. <i>Journal of Geriatric Oncology</i> , 2019, 10, 405-410.	1.0	17
17	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. <i>Clinical Cancer Research</i> , 2018, 24, 3292-3298.	7.0	41
18	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1906-1918.	1.1	88

#	ARTICLE	IF	CITATIONS
19	Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Nonâ€Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 441-449.e4.	2.6	65
20	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Nonâ€Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1156-1170.	1.1	195
21	Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. <i>Nature Medicine</i> , 2018, 24, 1441-1448.	30.7	936
22	Prospects and progress of atezolizumab in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 781-789.	3.1	13
23	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet, The</i> , 2017, 389, 255-265.	13.7	3,872
24	Treatment of limited disease small cell lung cancer: the multidisciplinary team. <i>European Respiratory Journal</i> , 2017, 50, 1700422.	6.7	17
25	Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Nonâ€Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 43-49.	2.6	31
26	Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine &ndash; a Phase I trial. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1081-1089.	2.0	18
27	Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9001-9001.	1.6	16
28	Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Nonâ€Small Cell Lung Cancer: A Phase I Dose EscalationÂStudy. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2208-2217.	1.1	66
29	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1837-1846.	13.7	2,390
30	Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9028-9028.	1.6	16
31	Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9032-9032.	1.6	14
32	Quality of Life in Patients with NSCLC Receiving Maintenance Therapy. <i>Cancers</i> , 2015, 7, 950-962.	3.7	4
33	Reply to B.M. Strebels. <i>Journal of Clinical Oncology</i> , 2014, 32, 479-480.	1.6	0
34	Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Nonâ€Small-Cell Lung Cancer: AVAPERL (MO22089). <i>Journal of Clinical Oncology</i> , 2013, 31, 3004-3011.	1.6	301
35	Health-Related Quality of Life in Patients with Advanced Nonsquamous Nonâ€Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089). <i>Journal of Thoracic Oncology</i> , 2013, 8, 1409-1416.	1.1	24
36	Smoking Cessation in Lung Cancer. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2013, 110, 719-24.	0.9	23